Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
An analysis of outcomes for infant allogeneic hematopoietic transplant recipients finds mixed results, with some signs of progress but no recent survival gains in patients with malignant diagnoses.
Azacitidine could help patients with acute myelogenous leukemia or myelodysplastic syndrome who relapse after transplant achieve remission.
Although studies have established the prognostic significance of specific genetic mutations in AML and MDS, the role of mutations as prognostic factors of outcomes after HCT is still unclear.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A multicenter team studied the safety of immunotherapy atezolizumab in patients with myelodysplastic syndrome who had either failed or never received conventional HMA therapy.